MOA Study of Ze 339 in Seasonal Allergic Rhinitis

Inclusion Criteria: * Allergic rhinitis since at least 2 years * Age: = \> 18 years * Consent in accordance with the AMG (=German Drug Law) * Positive skin test, skin prick test or positive RAST for grasses The skin prick test is positive if the wheal is \>= 3 mm greater than control; a skin test is positive if the wheal is \>= 7 mm greater than control * Women of childbearing potential have to use a highly effective method of birth control (according CPMP/ICH/286/95 Note 3) during the duration of the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner. Exclusion Criteria: * Past or current psychological disease or disorder which can impair the study participant's ability to understand the study requirements, t take part in the study or give consent after briefing * Past or current alcohol or medication dependency or abuse * Bronchial asthma (FEV \< 80 %) * Glaucoma, cataract or ocular herpes simplex * Clinically relevant deviations from normal laboratory parameters (if known) * Antihistamines with a long-term effect * Malignant diseases, including in the patient's case history * Parasites * Study participants who are taking part in another study or took an investigational product during the last 4 weeks before the start of treatment * Progressive systemic diseases such as tuberculosis, leukoses, collagenoses, multiple sclerosis, Aids, HIV infection and other autoimmune diseases * Other types of rhinitis with different causes, acute or chronic sinusitis * Pregnancy or lactation * Serious internal diseases, e.g. serious decompensated diseases of the heart, liver, kidneys or diabetes mellitus * Patients with rarely occurring hereditary problems galactose-intolerance, Lapp-lactase-deficiency or glucose-galactose-malabsorption * Pre-existing liver damage * The use of non-steroidal antirheumatic agents (NSAR) * Hypersensitivity towards one of the ingredients in the investigational product * Not adhering to the following periods of abstention before the nasal provocation test: 3 days for DNCG, nedocromil, nasal and oral antihistamines, and tricyclic psychotropic drugs, 1 months systemic treatment with glucocorticoids, 14 days for nasal and topical corticosteroids, 1 week for antihistamines, and 1 day for α-adrenergic drugs. The use of ACE inhibitors or ß-blockers * Previous organ transplants